Elevations in blood glucose before and after the appearance of islet autoantibodies in children

Journal article

There is a growing understanding that the early phases of type 1 diabetes (T1D) are characterised by a deleterious dialogue between the pancreatic beta cells and the immune system. This, combined with the urgent need to better translate this growing knowledge into novel therapies, provided the background for the JDRF-DiabetesUK-INNODIA-nPOD symposium entitled 'Islet cells in human T1D: from recent advances to novel therapies', which took place in Stockholm, Sweden, in September 2022. We provide in this article an overview of the main themes addressed in the symposium, pointing to both promising conclusions and key unmet needs that remain to be addressed in order to achieve better approaches to prevent or reverse T1D

Authors: Warncke, K; Weiss, A; Achenbach, P; von dem Berge, T; Berner, R

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: American Society for Clinical Investigation
• Journal: The Journal of Clinical Investigation
• Volume: 132
• Issue: 20
• Pages: e162123
• Article number: e162123
• Publication date: 2022-10-16
• DOI: 10.1172/jci162123
• EISSN: 1558-8238
• ISSN: 0021-9738
• Language: English
• Keywords: Islet; Immunology; Antibody; Diabetes mellitus; Autoantibody; Internal medicine; Endocrinology; Medicine